M. Stahl (Berlin, Germany), P. Robinson (Sydney (NSW), Australia)
This session is built from abstracts published on the ERS Congress platform from 23 August, in an e-poster pdf format with a 3-minute audio narration. Participants and chairs of the session are invited to access all e-posters from 23 August to 4 September prior to the 1-hour live, online discussion scheduled from September 5-7. Please note that during live discussion there will be NO e-poster/abstract presentations, only discussion.
Real-world effects of lumacaftor/ivacaftor (LUM/IVA) in people with cystic fibrosis (pwCF): interim results of a long-term safety study using US CF Foundation Patient Registry (CFFPR) data
C. Kim (Boston, United States of America), C. Lee (Boston, United States of America), R. Zahigian (Boston, United States of America), N. Nair (Boston, United States of America), A. Sewall (Bethesda, United States of America), A. Elbert (Bethesda, United States of America)
|   |
Real-world effects of tezacaftor/ivacaftor (TEZ/IVA) in people with cystic fibrosis (pwCF): interim results of a long-term safety study using US CF Foundation Patient Registry (CFFPR) data
J. Bower (Boston, United States of America), J. Shih (Boston, United States of America), V. Seliger (Boston, United States of America), D. Campbell (Boston, United States of America), I. Berhane (Boston, United States of America), R. Wu (Bethesda, United States of America), A. Elbert (Bethesda, United States of America)
| |
Observational study of ivacaftor in people with cystic fibrosis and selected non-G551D gating mutations: final results from VOCAL
N. Simmonds (London, United Kingdom), K. Van Der Ent (Utrecth, Netherlands), C. Colombo (Milan, Italy), N. Kinnman (Boston, United States of America), C. Desouza (Boston, United States of America), T. Thorat (Boston, United States of America), K. Chandarana (Boston, United States of America), C. Castellani (Genoa, Italy)
| |
The impact of Symkevi (Tezacaftor/Ivacaftor) on exercise capacity in adolescents with CF
M. Ahmed (Leicester (Leicestershire), United Kingdom), N. Dayman (Leicester (Leicestershire), United Kingdom), J. Madge (Leicester (Leicestershire), United Kingdom), E. Gaillard (Leicester (Leicestershire), United Kingdom)
| |
Respiratory microbiology outcomes from an observational study of ivacaftor in people with cystic fibrosis and non-G551D gating mutations (VOCAL)
C. Castellani (Genoa, Italy), N. Simmonds (London, United Kingdom), C. Colombo (Milan, Italy), N. Kinnman (Boston, United States of America), C. Desouza (Boston, United States of America), T. Thorat (Boston, United States of America), M. Chew (Boston, United States of America), K. Chandarana (Boston, United States of America), K. Van Der Ent (Utrecht, Netherlands)
| |
Effect of CFTR modulators on exercise tolerance and hand grip strength in CF children
M. Ahmed (Leicester (Leicestershire), United Kingdom), K. Dixon (Leicester (Leicestershire), United Kingdom), R. Butcher (Leicester (Leicestershire), United Kingdom), N. Dayman (Leicester (Leicestershire), United Kingdom), E. Gaillard (Leicester (Leicestershire), United Kingdom)
| |
LSC - 2021 - Effect of elexacaftor-tezacaftor-ivacaftor on pulmonary and endothelial function in a patient with advanced cystic fibrosis
R. Saša, M. Janic (mjanic@gmail.com / Department for endocrinology, d. and metabolic diseases, U. Medical Centre,Ljubljana), M. Lunder (mojca.lunder@kclj.si / Department for endocrinology, d. and metabolic diseases, U. Medical Centre,Ljubljana), M. Šabovic (miso.sabovic@kclj.si / Department of vascular diseases, U. Medical Centre,Ljubljana), B. Salobir (barbara.salobir.pulmo@kclj.si / Department of pulmonology, U. Medical Centre,Ljubljana)
| |
TNF and LTA gene polymorphisms in cystic fibrosis patients with Burkholderia cepacia complex (Bcc)
D. Pukhalskaya ( Moscow, Russian Federation), V. Shmarin ( Moscow, Russian Federation), T. Bukina ( Moscow, Russian Federation), S. Krasovsky ( Moscow, Russian Federation), S. Semykin ( Moscow, Russian Federation), M. Usacheva ( Moscow, Russian Federation), L. Avakian ( Moscow, Russian Federation), N. Kashirskaya ( Moscow, Russian Federation), G. Shmarina ( Moscow, Russian Federation)
| |
Inflammation in cystic fibrosis patients: study of the eicosanoid pathway and severity correlations.
S. Gartner (Barcelona, Spain), P. Fernandez-Alvarez (Barcelona, Spain), I. Lima (Barcelona, Spain), S. Rovira (Barcelona, Spain), C. Picado (Barcelona, Spain), E. Garcia-Arumí (Barcelona, Spain), I. De Mir (Barcelona, Spain), A. Torrent (Barcelona, Spain), A. Moreno (Barcelona, Spain), I. Iglesias (Barcelona, Spain), E. Tizzano (Barcelona, Spain)
| |
The persistence of Nontypeable Haemophilus Influenzae fuels type 17 immunity in the lung
F. Saliu (Milano (MI), Italy), G. Rizzo (Milano (MI), Italy), A. Bragonzi (Milano (MI), Italy), L. Cariani (Milano (MI), Italy), D. Cirillo (Milano (MI), Italy), C. Colombo (Milano (MI), Italy), V. Daccò (Milano (MI), Italy), D. Girelli (Milano (MI), Italy), S. Rizzetto (Milano (MI), Italy), C. Cigana (Milano (MI), Italy), N. Lore' (Milano (MI), Italy)
| |